The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial.

scientific article published on 30 September 2017

The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/CEI.13061
P932PMC publication ID5758380
P698PubMed publication ID28963724

P50authorErnesto MorenoQ54271568
Enrique MonteroQ89109529
Patricia HernandezQ89109531
P2093author name stringR Torres
J P Martínez
A M López
M V Hernández
J A Gómez
P C Rodríguez
C Viada
C Molinero
D M Prada
I M Hernández
J M Milera
L E Aira
Y Avila
Y Barrese
Y Reyes
P2860cites work6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, SwitzerlandQ42732008
A novel human T cell antigen preferentially expressed on mature T cells and shared by both well and poorly differentiated B cell leukemias and lymphomas.Q42799131
Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide DQ43205844
Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance reportQ45180236
Anemia and renal function in patients with rheumatoid arthritis.Q46514198
American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritisQ47643186
Health-related quality of life in fibromyalgia patients: a comparison with rheumatoid arthritis patients and the general population using the SF-36 health survey.Q48367538
Aberrant expression of CD6 on B-cell subsets from patients with Sjögren's syndrome.Q51038812
Humanization of Predicted T-Cell Epitopes Reduces the Immunogenicity of Chimeric Antibodies: New Evidence Supporting a Simple MethodQ51820107
Towards the definition of a chimpanzee and human conserved CD6 domain 1 epitope recognized by T1 monoclonal antibody.Q52839720
Immunologic responses of progressive multiple sclerosis patients treated with an anti-T-cell monoclonal antibody, anti-T12.Q54145863
T cell activation regulates CD6 alternative splicing by transcription dynamics and SRSF1.Q54348065
Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin‐17A productionQ54406138
Evidence for the expression of a second CD6 ligand by synovial fibroblastsQ60975375
High circulating levels of soluble scavenger receptors (sCD5 and sCD6) in patients with primary Sjögren's syndromeQ74523535
Analysis of type 1 and type 2 T cells in synovial fluid and peripheral blood of patients with rheumatoid arthritisQ77123551
Cytokine-regulated expression of activated leukocyte cell adhesion molecule (CD166) on monocyte-lineage cells and in rheumatoid arthritis synoviumQ77742364
CD6 molecule may be important in the pathological mechanisms of lymphocytes adhesion to human skin in psoriasis and ior t1 MAb a possible new approach to treat this diseaseQ78085988
Role of Th17 cells in human autoimmune arthritisQ84488292
Phenotypical characterization of human Th17 cells unambiguously identified by surface IL-17A expressionQ84754845
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility lociQ24656799
Leukotrienes, mast cells, and T cellsQ24795112
The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisQ27860872
CD6 and syntaxin binding protein 6 variants and response to tumor necrosis factor alpha inhibitors in Danish patients with rheumatoid arthritisQ28728734
Restoring the balance: immunotherapeutic combinations for autoimmune diseaseQ33555986
Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumabQ33573621
Cytokine pathways and joint inflammation in rheumatoid arthritisQ33939087
Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritisQ34315745
CD6 as a therapeutic target in autoimmune diseases: successes and challenges.Q34337963
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trialQ34530459
Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic reviewQ34574374
A comparison of multiplex suspension array large-panel kits for profiling cytokines and chemokines in rheumatoid arthritis patientsQ35586904
CD6 attenuates early and late signaling events, setting thresholds for T-cell activationQ35818957
Social aspects of living with rheumatoid arthritis: a qualitative descriptive study in Soweto, South Africa - a low resource contextQ36817685
Immunological evaluation of rheumatoid arthritis patients treated with itolizumabQ37138277
Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical reviewQ37158791
A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritisQ37390483
Randomized controlled trial design in rheumatoid arthritis: the past decadeQ37397646
Long-term outcomes of rheumatoid arthritisQ37431424
Rheumatoid arthritis and anemia: the impact of different anti-inflammatory therapies on hemoglobin levels. An observational studyQ38123838
Emerging cell and cytokine targets in rheumatoid arthritisQ38161794
Immunocompetent properties of human osteoblasts: interactions with T lymphocytesQ38317712
CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interactionQ38341487
Tuning T Cell Activation: The Function of CD6 At the Immunological Synapse and in T Cell Responses.Q38509507
Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and ItolizumabQ38722576
Community-based study to estimate prevalence and burden of illness of rheumatic diseases in Cuba: a COPCORD studyQ39876671
Expression and characterization of a novel CD6 ligand in cells derived from joint and epithelial tissuesQ40495317
P433issue2
P921main subjectrheumatoid arthritisQ187255
lymphopeniaQ485831
phase I clinical trialQ5452194
P304page(s)229-239
P577publication date2017-11-16
P1433published inClinical and Experimental ImmunologyQ15716708
P1476titleThe anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial
P478volume191